ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interferon"

  • Abstract Number: 0792 • ACR Convergence 2023

    Single Cell RNA-seq of Myeloid Cells from Systemic Sclerosis Patients Identifies Circulating Monocyte Population with Interferon Signature Associated with Interstitial Lung Disease

    Richard Ainsworth1, Kim Taylor2, Ye Cao3, Takanori Sasaki4, Deepak Rao5, Nunzio Bottini6 and Francesco Boin1, 1Cedars-Sinai Medical Center, Los Angeles, CA, 2University of California San Francisco, San Francisco, CA, 3Brigham and Women's Hospital, Boston, MA, 4Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Brigham and Women's Hospital, Boston, MA, 6University of California, San Francisco, CA

    Background/Purpose: Growing evidence supports a critical role for innate immunity in systemic sclerosis (SSc) pathogenesis. Altered myeloid cell numbers and functions have been implicated in…
  • Abstract Number: 1660 • ACR Convergence 2023

    Still’s Disease Patients with High Interferon-stimulated Gene Expression Have Enrichment of Rare, de Novo and Recessive Protein Altering Variants in Innate Immune Pathways

    Mariana Correia Marques1, Zuoming Deng2, Navid Chowdhury2, Elizabeth Schmitz3, Alana Platukus4, Stephen Brooks5, Carol Lake2, Ly-Lan Bergeron2, Michelle Millwood2 and Michael Ombrello6, 1National Institute of Arthritis & Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), St. Louis, MO, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Philadelphia, PA, 5Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skins Diseases, National Institutes of Health, Bethesda, MD, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD

    Background/Purpose: Still’s disease (systemic juvenile idiopathic arthritis in children, adult-onset Still’s disease in adults) is an enigmatic inflammatory condition that affects people of all ages.…
  • Abstract Number: 0010 • ACR Convergence 2023

    A Potential Mechanism for Major Adverse Cardiac Events Associated with JAK Inhibitors: JAK Inhibitor Withdrawal Causes Urokinase Release by Primed STAT Signaling

    Sara McCoy1, Ilya Gurevic2 and jacques Galipeau2, 1University of Wisconsin School of Medicine and Public Health, Middleton, WI, 2University of Wisconsin, Madison, WI

    Background/Purpose: Sjögren’s Disease (SjD) has high glandular IFNg levels, associated with disease activity and lymphoma risk. We showed that IFNg-stimulated minor salivary gland (SG)-mesenchymal stromal…
  • Abstract Number: 0886 • ACR Convergence 2023

    Neonatal Roseolovirus Infection Predisposes to Development of Lupus-like Disease After TLR7 Stimulation

    Tarin Bigley1, Eden Xue1, Lifei Zhu1, Li-ping Yang1 and wayne Yokoyama2, 1Washington University in St. Louis, St. Louis, MO, 2Washington University School of Medicine, St. Louis, MO

    Background/Purpose: Viral infections have been implicated as major factors in autoimmune disease but demonstrating causality is often challenging. We found that neonatal infection with a…
  • Abstract Number: 1664 • ACR Convergence 2023

    Fibroblast Specific Interferon Regulatory Factor 7 (IRF7) Expression Is a Key Link Between Type I Interferon Activation and the Exaggerated Dermal and Pulmonary Fibrosis in Systemic Sclerosis

    Minghua Wu1, Jerry Alonso2, Julio charles2, Brian Skaug2, Tingting Mills3, Maureen Mayes2 and Shervin Assassi4, 1Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, 2Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, 3Biochemistry Department, University of Texas McGovern Medical School, Houston, TX, 4University of Texas McGovern Medical School at Houston, Houston, TX

    Background/Purpose: A prominent interferon (IFN) activation signature has been observed at the peripheral blood and end-organ levels in systemic sclerosis (SSc). However, the mechanisms by…
  • Abstract Number: 0055 • ACR Convergence 2023

    Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses

    Wenyan Miao1, Daniel Rios1, Mehrnaz Gharaee-Kermani2, Craig Dobry2, Artur Jaroszewicz1, Cedric Arisdakessian1, Enrique Garcia-Rivera1, Nafeeza Hafeez1, Brian Desrosiers1, Jess Floro1, Jared Steranka1, Menachem Fromer1, Dennis Zaller1 and J. Michelle Kahlenberg2, 1Rome Therapeutics, Boston, MA, 2University of Michigan, Ann Arbor, MI

    Background/Purpose: Long Interspersed Element-1 (LINE-1) are retrotransposable DNA elements that make up ~17% of the human genome, and their role in health and disease is…
  • Abstract Number: 0891 • ACR Convergence 2023

    Selective and Potent Inhibition of Cyclic GMP-AMP Synthase (cGAS) Fully Normalizes Autoinflammation Across Tissues in a Trex1-/- Mouse Model for Type I Interferonopathies

    Arnaud Bourin1, Zuzana Hořejší2, Isabelle Cambré1, Juraj Dobiaš2, Mikhail Klychnikov2, Radek Liboska2, Maroš Smolíček2, Zdeněk Vavřina2, Wanda Haeck1, Hugo Klaassen1, Marnik Nijs1, Kristine Metzger1, Sandro Boland1, Dries De Clercq1, Sara Allasia1, Gunter Carlens1, Patrick Chaltin3, Arnaud Marchand1, Ondřej Páv2, Matthias Versele1 and Gabriel Birkuš2, 1Centre for Drug Design and Discovery (CD3) - Cistim, Leuven, Belgium, 2Institute of Organic Chemistry and Biochemistry, Prague, Czech Republic, 3Centre for Drug Design and Discovery (CD3) - KU Leuven, Leuven, Belgium

    Background/Purpose: The cGAS enzyme is a sensor of cytosolic double-strand (ds) DNA. It serves to detect viruses and elicits an acute, transient cGAMP-STING mediated type…
  • Abstract Number: 1665 • ACR Convergence 2023

    Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis

    Hanlin Yin1, Oliver Distler2, Bin Li3, Qingran Yan4 and Liangjing Lu1, 1Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China, 2Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 3Shanghai institute of immunology, Shanghai, China, 4Department of Rheumatology, Renji Hospital, Shanghai Jiaotong Univeisty School of medcine, Shanghai, China

    Background/Purpose: Type I interferon (IFN-1) signature is a hallmark of patients with systemic sclerosis (SSc). However, its significance in clinical stratification and contribution to deterioration…
  • Abstract Number: 0056 • ACR Convergence 2023

    The Activation of cGAS-STING Pathway in Systemic Lupus Erythematosus

    Jie An1, Stephen Wilson2, Jill Henault3 and Keith Elkon1, 1University of Washington, Seattle, WA, 2Bristol Myers Squibb, Cambridge, MA, 3Bristol Myers Squibb, Acton, MA

    Background/Purpose: The majority of patients with SLE show a striking Type I Interferon (IFN-I) signature in their peripheral blood. Although this signature can be generated…
  • Abstract Number: 0893 • ACR Convergence 2023

    Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model

    Trine Jorgensen and Lindsey Han, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can cause damage to multiple organs, including the kidneys in Lupus Nephritis (LN). Current treatments…
  • Abstract Number: 1708 • ACR Convergence 2023

    In Cis SOCS1 Variants Illustrate the Precise Regulation of Interferon Signaling Needed to Prevent Autoimmunity

    Yan Du1, Evan Hsu2, Kailey Brodeur3, Meng Liu4, Mindy Lo5, Craig Platt3 and Pui Lee5, 1Harvard medical school, Boston, MA, 2Wesleyan University, Newton, MA, 3Boston Children's Hospital, Boston, MA, 4Southern Medical University, Boston, MA, 5Division of Immunology, Boston Children's Hospital, Boston, MA

    Background/Purpose: Systemic autoimmunity can be driven by monogenic or polygenic risk variants. We aimed to characterize the genetic basis of disease in a family with…
  • Abstract Number: 0091 • ACR Convergence 2023

    Impaired X-Chromosome Inactivation Maintenance in T Cells Is Associated with Features of Reduced Disease Severity in a Toll-Like Receptor 7-Driven Model of Systemic Autoimmunity

    Nikhil Jiwrajka1, Zowie Searcy2, Claudia Lovell2, Natalie Toothacre2, Katherine Forsyth2 and Montserrat Anguera2, 1Divison of Rheumatology, Department of Medicine, Hospital of the University of Pennsylvania, Phildelphia, PA, 2Department of Biomedical Sciences, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA

    Background/Purpose: Many systemic autoimmune rheumatic diseases, including systemic lupus erythematosus (SLE), Sjögren's syndrome, and systemic sclerosis are highly female-biased. Although these diseases are more prevalent…
  • Abstract Number: 0894 • ACR Convergence 2023

    The Cellular and Spatial Type I Interferon Response Following Skin Exposure to Ultraviolet Light

    Jie An1, Xizhang Sun1, Rayan Najjar1, Connie Zhao1, Paul Kong2, Stephanie Weaver2, Amanda Koehne2, Matt Fitzgibbon2 and Keith Elkon1, 1University of Washington, Seattle, WA, 2Fred Hutchinson Cancer Center, Seattle, WA

    Background/Purpose: SLE patients characteristically have a prominent type I interferon (IFN-I) signature in lesional and non-lesional skin. We recently demonstrated that, following a single exposure…
  • Abstract Number: 1922 • ACR Convergence 2023

    Use of Plasma with High Titer Neutralizing Autoantibodies to Type I Interferons in Patients with Severe Refractory Flare-up of Hidradenitis Suppurativa as Novel Passive Immunotherapy Approach: Trial Protocol

    Charline Vauchy1, Maxime Desmarets1, Paul Bastard2, Anne Puel2, Pascale Richard3, Jean Laurent Casanova2, Pierre Tiberghien3, Eric Toussirot4 and Francois Aubin5, 1INSERM CIC-1431, Besançon, France, 2IHU Imagine, AP-HP Necker, Paris, France, 3Etablissement Français du Sang, St. Denis, France, 4University Hospital of Besancon, Besançon, France, 5Dermatology, University Hospital of Besancon, Besançon, France

    Background/Purpose: Hidradenitis suppurativa (HS) is a multifactorial auto-inflammatory disorder with a prevalence of 1% in North American and European populations. HS may be associated with…
  • Abstract Number: 0093 • ACR Convergence 2023

    Single Cell RNA-seq and Mass Cytometry Reveal a Cytotoxic CD8 Effector T Cell Population Associated with Interstitial Lung Disease in Systemic Sclerosis Patients

    Ye Cao1, Takanori Sasaki2, Richard Ainsworth3, Kim Taylor4, Nunzio Bottini5, Mehreen Elahee6, Edy Kim7, Francesco Boin3 and Deepak Rao7, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4University of California San Francisco, San Francisco, CA, 5University of California, San Francisco, CA, 6University of Pittsburgh Medical Center, Pittsburgh, PA, 7Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and mortality in systemic sclerosis (SSc). We aimed to identify features of circulating immune…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology